 |
Pharming Group N.V. (AMS:PHARM) Pharming And Aslan Group Sign License Agreement For Lactoferrin
NOV 18, 2008 23:37 - Article Views: 579
Pharming Group N.V. (AMS:PHARM) Pharming to receive significant milestone and royalty payments
|
 |
|
Pharming Group N.V. (AMS:PHARM) Pharming Announces Third Quarter 2008 Results
OCT 17, 2008 15:03 - Article Views: 249
Pharming Group N.V. (AMS:PHARM) Significant progress with lead product Rhucin®
|
|
|
Pharming Group N.V. (AMS:PHARM) Pharming Shareholders Appoint Sijmen De Vries As New CEO
OCT 14, 2008 00:33 - Article Views: 384
Pharming Group N.V. (AMS:PHARM) Leiden, The Netherlands, October 13, 2008. Biotech company Pharming Group NV ("Pharming" or "The Company") (Euronext: PHARM) announced today the appointment of Dr Sijmen de Vries as Chief Executive Officer (CEO) of Pharming. This decision was taken by the Shareholders at an Extraordinary Meeting (EGM) held earlier today. Dr de Vries will take up his position as of November 3, 2008 as successor to Dr Francis J. Pinto who will retire at the next Annual General Meeting of Shareholders (AGM) of the Company in 2009. Until then, Dr Pinto will stay on as Non-Executive Chairman of the Management Board to ensure a smooth transition.
|
|
|
Pharming Group N.V. (AMS:PHARM) Pharming's Board Of Supervisory Directors Nominates New CEO
SEP 26, 2008 16:03 - Article Views: 499
Pharming Group N.V. (AMS:PHARM) Dr Pinto to retire after completion of transition period
|
|
|
Pharming Group N.V. (AMS:PHARM) Pharming Provides Business Update At UBS Conference
SEP 23, 2008 02:17 - Article Views: 417
Pharming Group N.V. (AMS:PHARM) Database for Rhucin® Significantly Expanded
|
|
|
Pharming Group N.V. (AMS:PHARM) Pharming To Present At UBS Global Life Sciences Conference
SEP 18, 2008 02:03 - Article Views: 395
Pharming Group N.V. (AMS:PHARM) Leiden, The Netherlands, September 17, 2008. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it will present at the UBS Global Life Sciences Conference (September 22-25, 2008) in New York.
|
|
|
Pharming Group N.V. (AMS:PHARM) FDA Authorizes Investigational New Drug Application For Recombinant
Human C1 Inhibitor In Kidney Transplantation
SEP 3, 2008 16:03 - Article Views: 225
Pharming Group N.V. (AMS:PHARM) Leiden, The Netherlands, September 3, 2008. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that the US Food and Drug Administration (FDA) has authorized a clinical study with recombinant human C1 inhibitor (rhC1INH) for the treatment of antibody-mediated rejection (AMR) in kidney transplantation. Dr. Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with rhC1INH under an Investigator IND from the FDA.
|
|
|
Pharming Included In Amsterdam Midkap Index On NYSE Euronext
AUG 5, 2008 13:41 - Article Views: 240
Pharming Group N.V. (PINKSHEETS: PHGUF) Leiden, The Netherlands, August 4, 2008. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that its inclusion in the Amsterdam Midkap Index (AMX-index) has been confirmed by NYSE Euronext.
|
|
|
Pharming Announces First Half 2008 Results
JULY 18, 2008 15:03 - Article Views: 189
Pharming Group N.V. (PINKSHEETS: PHGUF) Regulatory filings moving forward with positive results from clinical studies with Rhucin®
|
|
